» Articles » PMID: 28010955

Three-year and Five-year Outcomes of Surgical Resection for Pancreatic Ductal Adenocarcinoma: Long-term Experiences in One Medical Center

Overview
Journal Asian J Surg
Publisher Elsevier
Specialty General Surgery
Date 2016 Dec 25
PMID 28010955
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Pancreatic ductal adenocarcinoma is one of the most malignant types of cancer. This study evaluated the 3-year and 5-year surgical outcomes associated with the cancer and determined whether statistically identified factors can be used to predict survival.

Methods: This retrospective review was conducted from 1995 to 2010. Patients who had resectable pancreatic ductal adenocarcinoma and received surgical treatment were included. Cases of hospital mortality were excluded. The relationships between several clinicopathological factors and the survival rate were analyzed.

Results: A total of 223 patients were included in this study. The 3-year and 5-year survival rates were 21.4% and 10.1%, respectively, and the median survival was 16.1 months. Tumor size, N status, and resection margins were independent predictive factors for 3-year survival. Tumor size independently predicted 5-year survival.

Conclusion: Tumor size is the most important independent prognostic factor for 3-year and 5-year survival. Lymph node status and the resection margins also independently affected the 3-year survival. These patient outcomes might be improved by early diagnosis and radical resection. Future studies should focus on the tumor biology of this aggressive cancer.

Citing Articles

A machine learning model based on preoperative multiparametric quantitative DWI can effectively predict the survival and recurrence risk of pancreatic ductal adenocarcinoma.

Qu C, Zeng P, Li C, Hu W, Yang D, Wang H Insights Imaging. 2025; 16(1):38.

PMID: 39962007 PMC: 11833029. DOI: 10.1186/s13244-025-01915-9.


Benefits of neoadjuvant chemotherapy with gemcitabine plus S-1 for resectable pancreatic ductal adenocarcinoma.

Hirashita T, Tada K, Nagasawa Y, Orimoto H, Kawamura M, Fujinaga A Mol Clin Oncol. 2025; 22(2):18.

PMID: 39776938 PMC: 11704984. DOI: 10.3892/mco.2024.2813.


Surgeon's Experience May Circumvent Operative Volume in Improving Early Outcomes After Pancreaticoduodenectomy.

Khan M, Muhammad S, Mehdi H, Parveen A, Soomro U, Ali J Cureus. 2023; 15(8):e42927.

PMID: 37667689 PMC: 10475154. DOI: 10.7759/cureus.42927.


Outcomes in patients with pancreatic ductal adenocarcinoma (PDAC) undergoing robotic (RPD) or open pancreaticoduodenectomies (OPD): a propensity score-weighted survival analysis.

Mejia A, Shah J, Vivian E, Beard R, Acharya P, Barrera Gutierrez J J Robot Surg. 2022; 17(3):1085-1096.

PMID: 36581740 DOI: 10.1007/s11701-022-01510-w.


Development and Validation of a Score for Screening Suicide of Patients With Neuroendocrine Neoplasms.

Lu L, Shang Y, Zechner D, Mullins C, Linnebacher M, Zhang X Front Psychiatry. 2021; 12:638152.

PMID: 34177643 PMC: 8225995. DOI: 10.3389/fpsyt.2021.638152.